TNF-α基因-308G/A位點多態性與前列腺癌易感性關系的Meta分析_《中國循證醫學雜志》

作者：

王莽原 ¹ , 韓振偉 ² , 劉嘉銘 ² ,  廖邦華 ²

1. 四川大學華西臨床醫學院（成都 610041）；2. 四川大學華西醫院泌尿外科（成都 610041）;

關鍵詞：

前列腺癌腫瘤壞死因子-α（TNF-α）多態性 Meta分析

DOI：

10.7507/1672-2531.20120160

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　采用Meta分析的方法評價TNF-α基因中–308G/A位點多態性和前列腺癌易感性之間的關系，為進一步闡明前列腺癌發病的分子機制及篩查前列腺癌高風險人群提供參考。
方法　計算機檢索PubMed（1950～2011）、EMbase（1990～2011）、CNKI、CBM、VIP和WanFang Data，按照納入與排除標準篩出關于TNF-α-308位點多態性與前列腺癌相關性的病例-對照研究或隊列研究，檢索時限均為從建庫至2012年1月。在提取數據和評價納入研究的方法學質量后，采用RevMan 5.1.4 和Stata 11.0 軟件進行統計分析。
結果　共納入11個研究，4 919例前列腺癌患者，5 210例健康對照。Meta分析結果顯示：① 前列腺癌組與對照組中基因型AA vs. GG［OR=0.92，95%CI（0.71，1.20），P=0.55］、GA vs. GG［OR=1.11，95%CI（0.90，1.37），P=0.33）、AA vs. GG + GA［OR=0.91，95%CI（0.70，1.18），P=0.47）、GA + AA vs. GG［OR=1.11，95%CI（0.90，1.36），P=0.33）、等位基因A vs. G［OR=1.07，95%CI（0.91，1.26），P=0.39］與前列腺癌易感性之間均無相關性；② 以人種為亞組進行分層分析，發現TNF-α–308位點的多樣性在不同人種中也無明顯相關性（P gt;0.05）。
結論　現有證據顯示，TNF-α–308位點等位基因和基因型可能與前列腺癌易感性無關。由于納入研究數量有限，上述結論尚需開展更多高質量、大樣本的隨機對照試驗加以驗證。

引用本文： 王莽原,韓振偉,劉嘉銘,廖邦華. TNF-α基因-308G/A位點多態性與前列腺癌易感性關系的Meta分析. 中國循證醫學雜志, 2012, 12(8): 1030-1034. doi: 10.7507/1672-2531.20120160 復制

1.	American Cancer Society: Cancer facts & ?gures. American Cancer Society, Atlanta, 2009.
2.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3.	Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4.	Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5.	Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6.	Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7.	Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8.	Duf?eld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9.	Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10.	Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11.	Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12.	Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13.	Bouraoui Y, Ricote M, García-Tuñón I, et al. Proin?ammatory cytokines and prostate speci?c antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14.	Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15.	Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16.	Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17.	OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18.	Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19.	Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20.	Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21.	Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22.	Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23.	Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24.	Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25.	Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26.	Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

1. American Cancer Society: Cancer facts & ?gures. American Cancer Society, Atlanta, 2009.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55: 74–108.
3. Hegarty NJ, Fitzpatrick JM, Richie JP, et al. Future prospects in prostate cancer. Prostate, 1999, 40: 261-268.
4. Ford D, Easton DF, Bishop DT, et al. Risk of cancer in BRCA1 mutation carriers. Lancet, 1994, 343: 692-695.
5. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet, 1998, 20: 175-179.
6. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Wash. DC), 1996, 274: 1371-1374.
7. Tavtigian SV, Simard J, Teng DH, et al. A strong candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet, 2001, 27: 172-180.
8. Duf?eld-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int, 2003, 91: 608-612.
9. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet, 1999, 64: 776-787.
10. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukocyte Biol, 1994, 55: 410.
11. Danforth KN, Rodriguez C, Hayes RB, et al. TNF Polymorphisms and Prostate Cancer Risk. Prostate, 2008, 68: 400-407.
12. Lee SO, Chun JY, Nadiminty N, et al. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate, 2007, 67: 764.
13. Bouraoui Y, Ricote M, García-Tuñón I, et al. Proin?ammatory cytokines and prostate speci?c antigen in hyperplasia and human prostate cancer. Cancer Detect Prev, 2008, 32: 23.
14. Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med, 1996, 334: 1717.
15. Zabaleta J, Lin HY, Sierra RA, et al. Interactions of cytokine gene polymorphisms in prostate cancer risk. Carcinogenesis, 2008, 29: 573-578.
16. Sáenz-López P, Carretero R, Cózar JM, et al. Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 2008, 8: 382.
17. OH BR, Sasaki M, Perinchery G, et al. Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol, 2000, 163: 1584-1587.
18. Wu HC, Chang CH, Chen HY, et al. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer. Urol Int, 2004, 73: 41-46.
19. Moore SC, Leitzmann MF, Albanes D, et al. Adipokine Genes and Prostate Cancer Risk. Int J Cancer, 2009, 124: 869-876.
20. Wang MH, Helzlsouer KJ, Smith MW, et al. Association of IL10 and other Immune response- and obesity-related genes with prostate cancer in CLUEII. Prostate, 2009, 69: 874-885.
21. Kesarwani P, Mandhani A, Mittal RD. Polymorphisms in Tumor Necrosis Factor-A Gene and Prostate Cancer Risk in North Indian Cohort. J Urol, 2009, 186: 2938-2943.
22. Ge JC, San YX. Studies on the relationship between single nucleotide polymorphisms and susceptibility to Prostate cancer in Chinese population. Zhengzhou University, Zhengzhou, China, 2007.
23. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer, 2003, 3: 276-285.
24. Wingerchuck D, Liu Q, Sobell J, et al. A population-based case-control study of the tumor necrosis factor alpha-308 polymorphism in multiple sclerosis. Neurology, 1997, 49: 626.
25. Nam RK, Zhang WW, Trachtenberg J, et al. Utility of Incorporating Genetic Variants for the Early Detection of Prostate Cancer. Clin Cancer Res, 2009, 15: 1787-1793.
26. Ferrer FA, Miller LJ, Andrawis RI, et al. Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology, 1998, 51: 161.

上一篇
我國示范鄉鎮衛生院基本藥物循證評價與遴選之二十：人工流產
下一篇
編前寄語

《中國循證醫學雜志》

TNF-α基因-308G/A位點多態性與前列腺癌易感性關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《中國循證醫學雜志》

TNF-α基因-308G/A位點多態性與前列腺癌易感性關系的Meta分析

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料